Staidson (Beijing) BioPharmaceuticals (SHE:300204) released the preliminary results for clinical trials for a drug that will treat patients with acute respiratory distress syndrome or ARDS, according to a Shenzhen bourse filing on Wednesday.
The Phase Ib/II clinical trials, which evaluates the safety and efficiency of the STSA-1002 injection, found that the drug showed mortality reductions of 33% and 85% for the low-dose and high-dose groups, respectively. The drug also showed clinical improvement rates of more than 70% for both groups.
The clinical trials received approval from the Chinese drug administration in March, the biopharmaceutical company said.
Staidson Bio's shares surged 20% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。